[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

NASDAQ Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [62b0e3d54029...] --------------------------------------------------------------- [Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing]( [See How Order 14017 Could Send This Company Skyrocketing]([aff_i?offer_...] --------------------------------------------------------------- July 7, 2022 From the desk of the Editor (Nasdaq's 5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- ["The Most Critical Metal for Global Economies"]( [e33a456c-e65...](The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year. [Find Out How This Is Good News for Commodity Investors.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Beyond Air, XAIR]( Recent Analyst Action: Scott Henry, analyst at Roth Capital, reiterates coverage on [Beyond Air (XAIR)](in the Technology sector with a Buy rating and a price target of $15 (1 week ago). - Recent Price: $$10.56 - Average Analyst Price Target: $17.75 (68.09%) - Market Cap: $$297.12M [TipRanks.com]( also reports that [Beyond Air](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.75. The target pricing ranges from a high forecast of $23.00 down to a low forecast of $13.00. [Beyond Air (XAIR)](’s last closing price was $$10.56 which would put the average price target at $$17.75. Here are 3rd party ratings for [XAIR](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 31% (78 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Knowing the Right People Can Change Your Life]( Most Americans don’t get to hear about companies like Microsoft or Amazon until IPO day – when 95% of the wealth’s been scooped off the table by early investors. That changes today. I’m leveling the playing field, and [I’m recruiting Mainstreet Americans to join me.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Avadel Pharmaceuticals, AVDL]( Recent Analyst Action: Ami Fadia, analyst at Needham, reiterates coverage on [Avadel Pharmaceuticals (AVDL)](in the Healthcare sector with a Buy rating and a price target of $6 (6 days ago). - Recent Price: $$3.98 - Average Analyst Price Target: $10.60 (166.33%) - Market Cap: $$217.84M [TipRanks.com]( also reports that [Avadel Pharmaceuticals](currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.60. The target pricing ranges from a high forecast of $19.00 down to a low forecast of $2.00. [Avadel Pharmaceuticals (AVDL)](’s last closing price was $$3.98 which would put the average price target at $$10.60. Here are 3rd party ratings for [AVDL](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 38% (95 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Trevi Therapeutics, TRVI]( Recent Analyst Action: Serge Belanger, analyst at Needham, reiterates coverage on [Trevi Therapeutics (TRVI)](in the Healthcare sector with a Buy rating and a price target of $10 (1 week ago). - Recent Price: $$3.77 - Average Analyst Price Target: $10.00 (165.25%) - Market Cap: $$144.30M [TipRanks.com]( also reports that [Trevi Therapeutics](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.00. The target pricing ranges from a high forecast of $10.00 down to a low forecast of $10.00. [Trevi Therapeutics (TRVI)](’s last closing price was $$3.77 which would put the average price target at $$10.00. Here are 3rd party ratings for [TRVI](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 31% (78 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Write These Three Ticker Symbols Down]( [5541affc-43f...](According to millionaire trader Jeff Clark, the stocks marked in this proprietary calendar are pre-determined to see big moves any day… all thanks to federal law 73-291. In his testing, he already doubled his money in 45 minutes with this strategy. And now he revealed the names of three of those stocks, completely free. [Click here to see the details and write them down.]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Celularity, CELU]( Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on [Celularity (CELU)](in the Services sector with a Buy rating and a price target of $15 (2 weeks ago). - Recent Price: $$3.94 - Average Analyst Price Target: $15.00 (280.71%) - Market Cap: $$566.61M [TipRanks.com]( also reports that [Celularity](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.00. The target pricing ranges from a high forecast of $15.00 down to a low forecast of $15.00. [Celularity (CELU)](’s last closing price was $$3.94 which would put the average price target at $$15.00. Here are 3rd party ratings for [CELU](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 31% (78 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Rigetti Computing, RGTI]( Recent Analyst Action: David Williams, analyst at Benchmark Co., reiterates coverage on [Rigetti Computing (RGTI)](in the Technology sector with a Buy rating and a price target of $12 (3 weeks ago). - Recent Price: $$4.88 - Average Analyst Price Target: $11.50 (135.66%) - Market Cap: $$530.63M [TipRanks.com]( also reports that [Rigetti Computing](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $11.50. The target pricing ranges from a high forecast of $12.00 down to a low forecast of $11.00. [Rigetti Computing (RGTI)](’s last closing price was $$4.88 which would put the average price target at $$11.50. Here are 3rd party ratings for [RGTI](: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 33% (167 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Holy Cow, Only $19!]( [e8f46695-76b...]("Hi, my name is Jeff Clark. For the past 36 years, I've shown people from all walks of life how to make money in the markets. Retired stockbrokers... presidents of companies... people with almost no financial experience... and everything in between. But I haven't done it the usual way… My method is different. It's unlike anything you’ve probably ever seen before. [We're unveiling it right now for just $19.]( That's the lowest price my publisher has EVER offered for a trading research service… And it won't be available for long. Watch a '10-second live demo' of this method to see how it works." [Watch Now]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Cardiff Oncology, CRDF]( Recent Analyst Action: Joseph Catanzaro, analyst at Piper Sandler, reiterates coverage on [Cardiff Oncology (CRDF)](in the Healthcare sector with a Buy rating and a price target of $7 (1 month ago). - Recent Price: $$3.11 - Average Analyst Price Target: $12.67 (307.40%) - Market Cap: $$128.19M [TipRanks.com]( also reports that [Cardiff Oncology](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.67. The target pricing ranges from a high forecast of $22.00 down to a low forecast of $7.00. [Cardiff Oncology (CRDF)](’s last closing price was $$3.11 which would put the average price target at $$12.67. Here are 3rd party ratings for [CRDF](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 31% (78 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [CareMax, CMAX]( Recent Analyst Action: Andrew Mok, analyst at UBS, reiterates coverage on [CareMax (CMAX)](in the Healthcare sector with a Buy rating and a price target of $12 (1 month ago). - Recent Price: $$5.04 - Average Analyst Price Target: $10.00 (98.41%) - Market Cap: $$416.75M [TipRanks.com]( also reports that [CareMax](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.00. The target pricing ranges from a high forecast of $12.00 down to a low forecast of $8.00. [CareMax (CMAX)](’s last closing price was $$5.04 which would put the average price target at $$10.00. Here are 3rd party ratings for [CMAX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 37% (156 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Copper More Critical than Lithium?]( [be7e813c-17c...](Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found. [See How You Can Benefit From New Copper Discoveries.](//trailer.web-view.net/Links/0XB0304D55570A7F4097463F0575A9113F26FBB2AAF674E84C18813D017CCA08AB6E42D31794A4AA26DC53CE864A3EED4C352254509B9EF0E1001B444F7491C4D0F598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it-- 7 Nasdaq 5 Day Gainers. Sincerely, Editor, MarketInsidersPress.com Newsletter Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com Sandpiper Marketing Group, LLC | | PO Box 407 | Mount Mourne | | North Carolina | 28123 | | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software